Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity

Introduction Sex-differences in biological treatment outcomes in adult patients with psoriasis are well known. Potential sex-differences in a real-world cohort of pediatric and young adult patients with psoriasis using biologics were investigated in this study.Methods Data on pediatric (<18 years...

Full description

Saved in:
Bibliographic Details
Main Authors: Malak Al-Gawahiri, Liana Barenbrug, Ewald M. Bronkhorst, Elke M. G. J. de Jong, Juul M. P. A. van den Reek, Marieke M. B. Seyger
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Dermatological Treatment
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2025.2532672
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849709795658956800
author Malak Al-Gawahiri
Liana Barenbrug
Ewald M. Bronkhorst
Elke M. G. J. de Jong
Juul M. P. A. van den Reek
Marieke M. B. Seyger
author_facet Malak Al-Gawahiri
Liana Barenbrug
Ewald M. Bronkhorst
Elke M. G. J. de Jong
Juul M. P. A. van den Reek
Marieke M. B. Seyger
author_sort Malak Al-Gawahiri
collection DOAJ
description Introduction Sex-differences in biological treatment outcomes in adult patients with psoriasis are well known. Potential sex-differences in a real-world cohort of pediatric and young adult patients with psoriasis using biologics were investigated in this study.Methods Data on pediatric (<18 years) and young adult (≥18 to ≤30 years) patients were obtained from the prospective, daily practice, ChildCAPTURE and BioCAPTURE registries. Drug survival and adverse event rates were compared between sexes. Confounder-corrected linear mixed models were used to compare Psoriasis Area and Severity Index (PASI) and (Children’s) Dermatology Life Quality Index ((C)DLQI) scores between sexes.Results We included 117 pediatric (65 females) and 243 young adult (124 females) patients on biologics (753.4 observation years). Young adult males had a significantly higher PASI at biologic initiation compared to females, with the same trend for pediatric patients. A higher adverse event rate was observed in females compared to males in both pediatric and young adult patients. Drug survival, PASI and (C)DLQI course during the first treatment year, were comparable between pediatric and young adult females and males.Conclusion Awareness on sex-differences (start PASI and adverse event rates) in pediatric and young adult patients with psoriasis is important for timely initiation and adjustment of appropriate treatment.
format Article
id doaj-art-348ddace79384fcabd07d2de47b4d6b4
institution DOAJ
issn 0954-6634
1471-1753
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Journal of Dermatological Treatment
spelling doaj-art-348ddace79384fcabd07d2de47b4d6b42025-08-20T03:15:09ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2025.2532672Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activityMalak Al-Gawahiri0Liana Barenbrug1Ewald M. Bronkhorst2Elke M. G. J. de Jong3Juul M. P. A. van den Reek4Marieke M. B. Seyger5Department of Dermatology, Radboud University Medical Center, Nijmegen, The NetherlandsDepartment of Dermatology, Radboud University Medical Center, Nijmegen, The NetherlandsDepartment of IQ Health, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The NetherlandsDepartment of Dermatology, Radboud University Medical Center, Nijmegen, The NetherlandsDepartment of Dermatology, Radboud University Medical Center, Nijmegen, The NetherlandsDepartment of Dermatology, Radboud University Medical Center, Nijmegen, The NetherlandsIntroduction Sex-differences in biological treatment outcomes in adult patients with psoriasis are well known. Potential sex-differences in a real-world cohort of pediatric and young adult patients with psoriasis using biologics were investigated in this study.Methods Data on pediatric (<18 years) and young adult (≥18 to ≤30 years) patients were obtained from the prospective, daily practice, ChildCAPTURE and BioCAPTURE registries. Drug survival and adverse event rates were compared between sexes. Confounder-corrected linear mixed models were used to compare Psoriasis Area and Severity Index (PASI) and (Children’s) Dermatology Life Quality Index ((C)DLQI) scores between sexes.Results We included 117 pediatric (65 females) and 243 young adult (124 females) patients on biologics (753.4 observation years). Young adult males had a significantly higher PASI at biologic initiation compared to females, with the same trend for pediatric patients. A higher adverse event rate was observed in females compared to males in both pediatric and young adult patients. Drug survival, PASI and (C)DLQI course during the first treatment year, were comparable between pediatric and young adult females and males.Conclusion Awareness on sex-differences (start PASI and adverse event rates) in pediatric and young adult patients with psoriasis is important for timely initiation and adjustment of appropriate treatment.https://www.tandfonline.com/doi/10.1080/09546634.2025.2532672Pediatric dermatologypsoriasispediatric psoriasisbiologic treatmentsex-disparities
spellingShingle Malak Al-Gawahiri
Liana Barenbrug
Ewald M. Bronkhorst
Elke M. G. J. de Jong
Juul M. P. A. van den Reek
Marieke M. B. Seyger
Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity
Journal of Dermatological Treatment
Pediatric dermatology
psoriasis
pediatric psoriasis
biologic treatment
sex-disparities
title Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity
title_full Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity
title_fullStr Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity
title_full_unstemmed Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity
title_short Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity
title_sort sex disparities in pediatric and young adult patients with psoriasis treated with biologics differences in adverse events and disease activity
topic Pediatric dermatology
psoriasis
pediatric psoriasis
biologic treatment
sex-disparities
url https://www.tandfonline.com/doi/10.1080/09546634.2025.2532672
work_keys_str_mv AT malakalgawahiri sexdisparitiesinpediatricandyoungadultpatientswithpsoriasistreatedwithbiologicsdifferencesinadverseeventsanddiseaseactivity
AT lianabarenbrug sexdisparitiesinpediatricandyoungadultpatientswithpsoriasistreatedwithbiologicsdifferencesinadverseeventsanddiseaseactivity
AT ewaldmbronkhorst sexdisparitiesinpediatricandyoungadultpatientswithpsoriasistreatedwithbiologicsdifferencesinadverseeventsanddiseaseactivity
AT elkemgjdejong sexdisparitiesinpediatricandyoungadultpatientswithpsoriasistreatedwithbiologicsdifferencesinadverseeventsanddiseaseactivity
AT juulmpavandenreek sexdisparitiesinpediatricandyoungadultpatientswithpsoriasistreatedwithbiologicsdifferencesinadverseeventsanddiseaseactivity
AT mariekembseyger sexdisparitiesinpediatricandyoungadultpatientswithpsoriasistreatedwithbiologicsdifferencesinadverseeventsanddiseaseactivity